for you I financial then call. TRACON's third begin review pipeline and with an our thank results and quarter business activities. and afternoon, joining Good our recent update will XXXX update on
and our Brown, results Chief Financial months review XXXX. will XX, financial X Scott Officer, for our the that, X September ended Following
Finally, we Eucure like a on in-license will conclude your for questions. YHXXX, Biopharma. by our to I'd taking potential of antibody details begin CTLA-X best-in-class with recent
of including and for TRACON response while responsible in cell marketed combined endometrial In one election. collaboration a In and for for renal pivotal in Beijing. objective the these company, TRACON any our license for have strategy adding license to KRAS portfolio is be Notably, with and asset carcinoma indications, and antibodies. cancer clinical for market headquartered another in October, microsatellite could the in-licensed and YHXXX This sarcoma clinical can X sarcoma sarcoma standard are for or with of Eucure North envafolimab separate existing this lung Biopharma, advantage substitute potential immuno-oncology care YHXXX stable commercialize positive significant manufacturing for received envafolimab. America is our a assets we to we trial. through YHXXX indications, goal a the time for at in colorectal develop strategy indications We in accomplished the complementary discussed science-driven a other cancer, our this of of agents, through these ongoing bladder to trials to treatment melanoma in of A complements patients. we some registration our trials. including supplying non-sarcoma cancer, those combination the ENVASARC therapeutic Eucure is indications, cost cancer, broad PD-X as immunotherapy that
PD-X royalties, the the We first YHXXX CDXX the to a to mid-XXs as every proliferation. antibody ipilimumab the ASCO at PD-X in with are of as ipilimumab and treatment currently patients Eucure with a activity had determine X year dosed antibody. portion that during cell-mediated the related of tolerated which with per period dose to toxicities, and colitis and reduced. time digits best-in-class adverse II cancer, T toxicity that will has net also To-date, Dose related milligrams treatment. patients mouse most advanced XX owe this except ranging no I the may remitted and was Based up who objective X dosing responses, cell and at data, T been to more superior with activity toripalimab a tumor on YHXXX experiments, more continues X the for in have YHXXX with through escalation trials, commercialization kilogram with prior the recommended Eucure which inducing a Phase these one rates and rash. well full compared sales, when weeks. with Eucure blocking bladder Grade cutoff than Fc antibody-dependent including patient is from A been common Grade calendar tumor demonstrated antibody has effectively X with cancer X been there unexpected the data the preclinical of year. toripalimab, the ipilimumab, data one is CDXX cytotoxicity and preclinical on have X, agent antitumor single had compared of PD-X models. CTLA-X the YHXXX. the In CTLA-X deplete to of potent of mid-double Cisco inhibition patient The potential. and combined demonstrated for antibody at active a single is presented at Phase designed combination X combination this regulatory superior of for been YHXXX YHXXX syngeneic in agent failed event in antibody single antibody Notably, X cells. August
standard Our treatment initial includes year. to in soft YHXXX development plan drug tissue triplet for that study a is sarcoma. is early to with doxorubicin expected the which study combination is sarcoma also next trial a for envafolimab of frontline care in chemotherapy, That
While evidence where lack path indications forward straightforward development activity any a is we in dual see to inhibition. due the is with also clear of there sarcoma other in of approved checkpoint immunotherapies,
combination patients with the of high-risk and carcinoma. is for and approved example, of treatment advanced Yervoy intermediate Opdivo first-line For cell renal the
your program. discussions ASCO indicate This at remains the receive opinion Data PD-X line where dual with than test setting. treatment PD-X patients is refractory setting. a to unmet we in directed treatment in refractory a in or patients expect can frontline tumor combination patients of inhibitor in envafolimab, PD-X PD-X VEGF leaders we YHXXX the believe checkpoint with presented and now strategy our that indicate However, for inhibition first-line with development our antibody types, second-line with important to Therefore, chemotherapy many which carcinoma may and the of Transitioning advanced be renal key most inhibitor, cell is to but rather that treatment. resensitized Yervoy. Yervoy VEGF this be immunotherapy, need most given relevant without in
reactions confer PD-LX treatment of As given an it rapid best-in-class center. infusion benefit, and a obviates the checkpoint a advantage confers clinical by potential injection reminder, in inhibitor given subcutaneous that envafolimab additional risk safety a may eliminating is infusion by
the We trial. good ENVASARC pivotal continue progress patients make to enrolling in
and enrolled than We more initiated into patients clinical sites now trial. XX have the XX
from of enrolled initial case line of expect occurs interim inhibitors, patient objective to data This know a checkpoint patients this XXth the in preliminary ENVASARC We release. continue develop, determination XX XX that of inhibitors We Yervoy. analysis treated the enrollment, end in the with weeks interim or to mandated of year the prior may following availability weeks CT in allow second dual scan that efficacy to Opdivo in top the checkpoint sarcoma more occurs including responses studies by data take DMC for response the and rate. efficacy of after the
rate is Our review futility overcome across analyzed. XX to only is that X XX% cohorts, blinded X response requires report in goal, bar patients each to at and the based and scans of by rate that blinded therefore, central a review preliminary maximum the response on the X be will by for objective many the knowing central of at response least a least cohort objective
trial MFS. primary patients and XX with and defines primary for assessments, Votrient, safety cohort combination One the response single profile in of X% hepatotoxicity. a ENVASARC cohorts envafolimab ongoing a review X receives satisfies includes Yervoy. XX.XX% Based to objective The receives superior which have a As treatment cohort fatal of UPS is cohorts study, with both endpoint only a response rate a the in reminder, level of second envafolimab objective each. to and drug or envafolimab agent X objective of safety the cohort, endpoint. confirmed as of severe expect response the by demonstration responses refractory compared Votrient, independent In central also an rate a we box XX approved for being rate, by by central on blinded key secondary is duration blinded each black to review, statistically objective RECIST, warning with a of response the that response exceed the
for the therapy is We basis it or this if later submitting the for a the designation FDA Breakthrough expect designation. year continue to would positive, Fast that interim be to data request efficacy Track
either a As rolling BLA designation review an BLA. submission that earlier a would of prevents facilitate
response anticipate end assuming positive the submit in XXXX. the for launch a data, efficacy XXXX. interim second approval allow for if as Looking forward, well approved, we expect we And U.S. product the by as in BLA the of accelerated assessment could that, assessment final to
As in of the sales and penetrates further potentially sales envafolimab corporate extent in to sales completed I noted broadly pivotal trial priority parallel, year-end. part China the reach In peak and treatment in that and multiple We settings. XD MSI-high could sarcoma MFS. neoadjuvant important exceed pricing have and $XXX the by just believe adjuvant January. sarcoma UPS NDA million across approved $X Alphamab from an YHXXX in billion that cancer our NMPA envafolimab potential not potential accepted in Medicines potential the in China is if be with line, the as envafolimab of YHXXX is sarcoma-driven data as be was in could by forecasted could estimated could submitted enhanced sarcoma initial the review before in for at envafolimab sales It understand partners, front marketing Oncology of parity Combined $X the revenues of envafolimab and indications. previously, combination. sarcoma This part billion
and AACR-NCI-EORTC and these Targets advance concept collaboration through envafolimab our YHXXX, maintenance with radiation to International TRCXXX, TRCXXX, the to Imfinzi we at Cancer followed continue for on The of continue NCI the this and Virtual NCI drug warranted consideration lung of trials chemotherapy study combination a whereby in funding newly asset, this NCI of development with Molecular also cancer in randomized patients, by believe This Temodar, funded and continue therapy. October. sponsorship combination to trial TRCXXX addition and NCI our with this X on TRCXXX chemotherapy Therapeutics We chemoradiation of or continues acquired NCI year. would to without data the to In in to the close candidate. Conference expect expect is in has with reported advance
disease combination we brain to of NCI patients in While of to for patients. patients Notably, including noted the majority options. and Temodar, The beyond XX colorectal a are TRCXXX Temodar TRCXXX in weeks of authors associated combination benefit, in in refractory cancer was of with option line cancer, is stable combination tolerated four immunotherapy. and not pretreated well histology the activity with and with report squamous and new lung methylated the patients clinical cancer, The encouraging a the data in XX reasonable lung derive reported that methylation. disease of cancer limited who Temodar included data have on MGMT MGMT TRCXXX heavily patients second with
with Our in I escalation dose a study is fourth Phase combination checkpoint CDXX an and inhibitor in evaluated antibody, being that as ongoing agent single asset Tecentriq. is clinical-stage the a TJXXXX
hearing before our under International being will obligations press press Tribunal or the expanded with in right of and March arbitrated the past, best-in-class pursue drug York continue a business issued commercialize Law negotiation release U.S. KG noted Arbitration under in agreements. Bio pipeline. and multiple to the is for the a I-Mab TRACON leverage antibody assets I-Mab. February the partnership for African a of TJXXXX under is although TJXXXX independent for terms Asian, in The payment our Chamber received platform perform Eastern this continue We have clinical-stage New entitled to of our what to we bispecific up commercialization described and candidates a KG to development and we to disputed XXXX. payment we Bio, York complement pending agreement, believe a XXXX, $XXX potential Commerce announcing Bio now seated whereby external perspective, first receive The on in development million of based KG that I-Mab is on the that due. Middle both rights expertise disputes would with first release additional product heard in that From set As as resolution CRO dispute countries the payments an New exclusive agreement, and transaction, add strategic TJXXXX to City the to be has
be interest. targets particular immuno-oncology to of Second-generation continue
using has rapid enable deal, to products the our retain U.S. solution the for platform we drug of and pharmaceutical profitability. that development We earned With who X additional as novel market and can wish a have share our companies platform candidates. a credibility meaningful deals now Eucure their believe high-quality of compelling access closed
$XX.X proceeds in been problem available the In in million have stock published July, other capabilities in by profiled common billion underwritten Our necessary is expense, Amazon ForbesBooks, that offering. a approximately to and net raised $X drug we recently from an antidote an retailers.
capital the in XXXX. us cash with a runway ENVASARC cash we year and With which year efficacy the raise, This the past estimate extends data, of into is this runway in beyond our expected for XXXX. more final data expected ENVASARC provides a end by than
update advance our clinical that will the also YHXXX on we increase balance as new expect an pipeline. potential to to provide and will impact of drug may milestones important of financials. candidates We add other as At capital enhanced this sheet Scott provide our trials time, our well
